NCT02492737 is a Phase 1 clinical trial of AG881 in Acute Myeloid Leukemia (AML), sponsored by Agios Pharmaceuticals, Inc..

Who is sponsoring NCT02492737?

NCT02492737 is sponsored by Agios Pharmaceuticals, Inc..

What drugs are being tested in NCT02492737?

Interventions in NCT02492737: AG881.

What condition does NCT02492737 study?

NCT02492737 studies Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies.

Is NCT02492737 still recruiting?

NCT02492737 is currently completed. Last updated 8 March 2019.

Last reviewed 2019-03-08 · How we verify

NCT02492737

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Completed Phase 1 Last updated 8 March 2019

What this trial tests

Phase 1 trial testing AG881 in Acute Myeloid Leukemia (AML) in 46 participants. Completed in 21 March 2018.

Timeline

7 August 2015

Primary endpoint
21 March 2018

21 March 2018

Quick facts

Lead sponsor	Agios Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	7 August 2015
Primary completion	21 March 2018
Estimated completion	21 March 2018
Sites	6 locations across France, United States

Drugs / interventions tested

AG881 — full drug profile →

Conditions studied

Acute Myeloid Leukemia (AML) — all drugs for Acute Myeloid Leukemia (AML) →
Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →
Hematologic Malignancies — all drugs for Hematologic Malignancies →

Sponsor

Agios Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The emerging role and targetability of the TCA cycle in cancer metabolism.
Anderson NM, Mucka P, Kern JG, Feng H. · · 2018 · cited 404× · PMID 28748451 · DOI 10.1007/s13238-017-0451-1
Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, et al · · 2017 · cited 257× · PMID 27721426 · DOI 10.1038/leu.2016.275
Energy metabolism in health and diseases.
Liu H, Wang S, Wang J, Guo X, et al · · 2025 · cited 178× · PMID 39966374 · DOI 10.1038/s41392-025-02141-x
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Golub D, Iyengar N, Dogra S, Wong T, et al · · 2019 · cited 176× · PMID 31165048 · DOI 10.3389/fonc.2019.00417
Mitochondria in cancer.
Grasso D, Zampieri LX, Capelôa T, Van de Velde JA, et al · · 2020 · cited 168× · PMID 32548570 · DOI 10.15698/cst2020.06.221
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
Mondesir J, Willekens C, Touat M, de Botton S. · · 2016 · cited 153× · PMID 27621679 · DOI 10.2147/jbm.s70716
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease.
Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, et al · · 2019 · cited 110× · PMID 31131326 · DOI 10.1126/sciadv.aaw4543

Verify or expand the search:

Other trials of AG881

Trials testing the same drug.

NCT04145128 — A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants · Phase 1 · completed
NCT03343197 — Study of AG-120 and AG-881 in Subjects With Low Grade Glioma · Phase 1 · completed

Other recruiting trials for Acute Myeloid Leukemia (AML)

Currently open trials in the same condition.

NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06707493 — Ivosidenib as Post-HSCT Maintenance for AML · Phase 2 · recruiting
NCT07458542 — Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia · active not recruiting

Other Agios Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT07075640 — A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the · Phase 1 · recruiting
NCT06745271 — A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat · Phase 1 · completed
NCT06648824 — Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants · Phase 1 · completed
NCT06286033 — Single and Multiple Ascending Dose Study and Food Effect Study for AG181 · Phase 1 · completed
NCT05610657 — A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Contro · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02492737 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Agios Pharmaceuticals, Inc.
Last refreshed: 8 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02492737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing